STOCK TITAN

Lineage Cell Therapeutics (LCTX) Stock News, Dec 2020-Feb 2021

LCTX NYSE

Lineage Cell Therapeutics, Inc. develops allogeneic, or “off-the-shelf,” cell therapies for serious medical conditions using its AlloSCOPE cell differentiation and expansion platform. Its pipeline includes OpRegen, also known as RG6501, for geographic atrophy secondary to age-related macular degeneration; OPC1 for spinal cord injury; ReSonance, or ANP1, for hearing loss; and COR1 for corneal endothelial disease.

Recurring company news covers clinical data presentations, preclinical program launches, manufacturing and platform updates, research collaborations, milestone activity, financial results, business updates, and scientific governance. Updates frequently connect Lineage’s cell transplant programs with ophthalmology, neurology, auditory disease, and other non-oncology therapeutic areas.

Rhea-AI Summary

Lineage Cell Therapeutics (NYSE American: LCTX) has announced a virtual Investor and Analyst Day scheduled for February 22, 2021, focusing on its OPC1 program aimed at treating acute spinal cord injuries. This program, which has received a $14.3 million grant from the California Institute for Regenerative Medicine, utilizes oligodendrocyte progenitor cell transplants to enhance motor recovery. The event will feature Dr. Edward Wirth, III, who will provide insights into the clinical data and discuss the ongoing partnership with Neurgain Technologies. Investors can access the live webcast through Lineage's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.67%
Tags
conferences
-
Rhea-AI Summary

Lineage Cell Therapeutics (LCTX) has signed an exclusive option and license agreement with Neurgain Technologies. The collaboration focuses on clinical testing of Neurgain's innovative Parenchymal Delivery Injection (PDI) system for administering OPC1, a cell therapy for spinal cord injury. The PDI aims to simplify procedures by eliminating the need to stop respiration during surgery, potentially enhancing safety and effectiveness. Lineage's CEO emphasizes that this advancement complements their ongoing work on OPC1, which has received RMAT and Orphan Drug designations from the FDA.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.42%
Tags
none
-
Rhea-AI Summary

Lineage Cell Therapeutics (LCTX) recently updated investors on its clinical advancements through webinars hosted by FORCE Wealth. The presentations covered three key product programs: OpRegen for dry age-related macular degeneration, OPC1 for acute spinal cord injuries, and VAC2 for cancer treatment. CEO Brian M. Culley emphasized the growing viability and market opportunity for allogeneic cell therapies. The company is gearing up for later-stage clinical trials, aiming to leverage supportive public policies and investor interest in cell therapy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.00%
Tags
none
Rhea-AI Summary

Lineage Cell Therapeutics (NYSE American: LCTX) announced the resignation of CFO Brandi Roberts on January 15, 2021, to pursue a leadership role elsewhere. She will assist in the transition as Brian Culley, the current CEO, steps in as Interim CFO. Brian praised Roberts for her contributions to restructuring and strengthening the company. Lineage is focused on developing allogeneic cell therapies for significant medical needs and has ongoing clinical programs targeting major health issues, including dry age-related macular degeneration and spinal cord injuries.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.00%
Tags
none
-
Rhea-AI Summary

Lineage Cell Therapeutics (LCTX), a clinical-stage biotech firm, presented a review of 2020 and outlined 2021 goals, emphasizing its commitment to treating serious diseases through innovative cell therapies. In 2020, the company reached significant clinical and manufacturing milestones, positioning itself for growth in a rapidly evolving industry. Lineage aims to advance its products through late-stage trials while leveraging a robust patent portfolio and in-house manufacturing capabilities. Importantly, it has avoided traditional equity financing by monetizing non-core patents, enhancing financial stability.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.41%
Tags
none

FAQ

What is the current stock price of Lineage Cell Therapeutics (LCTX)?

Lineage Cell Therapeutics (LCTX) last closed at $0.7719.

What is the market cap of Lineage Cell Therapeutics (LCTX)?

The market cap of Lineage Cell Therapeutics (LCTX) is approximately $195.3M.